Thus, we provide proof of principle in a preclinical model that the inhibition of HSP90A signaling is an appealing therapeutic strategy to incorporate with various cancer therapeutic modalities, particularly an immune-based modality, and overcome NANOGhigh immune-refractory tumors. The gene discussed is HSP90AA1; the disease is cancer.